z-logo
open-access-imgOpen Access
Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+T cells via CD40 ligand
Author(s) -
Konstantin Balashov,
Derek R. Smith,
Samia J. Khoury,
David A. Hafler,
Howard L. Weiner
Publication year - 1997
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.94.2.599
Subject(s) - cd40 , immune system , multiple sclerosis , secretion , medicine , t cell , immunology , endocrinology , antibody , pathogenesis , biology , cytotoxic t cell , biochemistry , in vitro
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system postulated to be a cell-mediated autoimmune disease in which interferon γ (IFN-γ) plays an important role. There is increased IFN-γ secretion in MS, and IFN-γ administration induces exacerbations of disease. We found that interleukin 12 (IL-12) was responsible for raised IFN-γ secretion in MS as anti-IL-12 antibodies reversed raised anti-CD3-induced IFN-γ in MS patients to normal levels. Furthermore, we found a marked increase in T cell receptor-mediated IL-12 secretion in progressive MS patients vs. controls (24.8 ± 7.7 pg/ml vs. 1.5 ± 1.0 pg/ml,P = 0.003) and vs. relapsing–remitting patients (3.7 ± 1.4 pg/ml,P < 0.05). Investigation of the cellular basis for raised IL-12 demonstrated that T cells from MS patients induced IL-12 secretion from non-T cells, and that T cells from MS patients could even drive non-T cells from normal subjects to produce increased IL-12. Anti-CD40 ligand antibody completely blocked IL-12 secretion induced by activated T cells, and we found increased CD40 ligand expression by activated CD4+ T cells in MS patients vs. controls. The CD40 ligand-dependent Th1-type immune activation was observed in the progressive but not in the relapsing–remitting form of MS, suggesting a link to disease pathogenesis and progression and providing a basis for immune intervention in the disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom